GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs AFM 13 (Primary)
- Indications Hodgkin's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms GHSG-AFM13
- Sponsors Affimed Therapeutics
- 03 Nov 2017 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 03 Nov 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
- 17 May 2017 According to an Affimed Therapeutics media release, full data from thsi study is anticipated in 2019.